Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corporation (UTHR) reported insider activity by its CFO and Treasurer on a Form 4. On 11/24/2025, the executive exercised 21,000 stock options at an exercise price of $146.03 per share, converting them into common stock. That same day, multiple blocks of common shares were sold in market transactions, with weighted average sale prices reported in ranges generally around $466.72 to $482.42 per share. After these transactions, the reporting person directly held 8,142 shares of United Therapeutics common stock. The filing notes that the option exercise and subsequent sales were carried out under a Rule 10b5-1 trading plan entered into on August 5, 2025, which is a pre-arranged plan intended to allow insiders to trade shares over time according to preset instructions.
United Therapeutics (UTHR) reported insider equity activity by its President and COO on 11/24/2025. Through trusts, the reporting person exercised stock options for 2,625, 12,000, and 7,875 shares of common stock at exercise prices of $117.76, $135.42, and $146.03 per share, respectively.
The same numbers of shares were then sold at a price of $473.6569 per share by the relevant trusts under a Rule 10b5-1 trading plan entered into on June 3, 2025. After these trust transactions, the reporting person shows 2,648 shares of United Therapeutics common stock held directly.
United Therapeutics Corp (UTHR) reported an insider stock transaction by its EVP & General Counsel. On 11/26/2025, the executive exercised 11,000 stock options at an exercise price of $135.42 per share, converting them into common stock.
On the same date, the resulting shares were sold in multiple open-market transactions under a pre-arranged Rule 10b5-1 trading plan entered into on December 24, 2024. The sales totaled several small blocks at weighted average prices ranging from about $483.05 to $488.13 per share. After these transactions, the reporting person directly owned 36,781 shares of United Therapeutics common stock.
United Therapeutics (UTHR) Chairperson and CEO reported option exercises and share sales in a Form 4 filing. On 11/24/2025 and 11/25/2025, the insider exercised a total of 8,000 stock options at an exercise price of $120.26 per share, converting them into common stock.
Across those two days, the insider sold shares in multiple transactions, including 2,500 and 1,500 shares on 11/24/2025 at weighted average prices of about $469.73 and $472.53, and 1,536, 2,164 and 300 shares on 11/25/2025 at weighted average prices around $473.69, $475.67 and $481.23. These trades were executed under a pre-arranged Rule 10b5-1 trading plan entered on May 2, 2025, which continues until a tranche of 294,000 options expiring on March 15, 2026 is exhausted or until December 31, 2025, whichever occurs first.
Following the reported transactions, the insider directly holds 130 shares, with additional indirect holdings through a spouse and several family trusts. Remaining stock options at the $120.26 exercise price total 66,000 and expire on March 15, 2026.
United Therapeutics Corp Chairperson and CEO, who is also a director, reported option exercises and related stock sales in a Form 4 filing. On 11/20/2025 and 11/21/2025, the reporting person exercised 4,000 stock options on each day at an exercise price of $120.26 per share and sold the resulting shares in multiple open‑market transactions around $473–$480 per share, using weighted average prices.
The transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan entered on May 2, 2025, which will continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring on March 15, 2026 or December 31, 2025. Following the reported transactions, the reporting person holds 130 shares of common stock directly, additional shares indirectly through a spouse and several family trusts, and stock options to purchase 74,000 shares at $120.26 per share.
United Therapeutics (UTHR) Chairperson & CEO reported option exercises and share sales in mid-November 2025. On 11/18/2025 and 11/19/2025, the executive exercised a total of 8,000 stock options at an exercise price of $120.26 per share and sold 8,000 shares of common stock at weighted average prices around $470–$475 per share. After these transactions, the executive held 130 shares directly and additional shares indirectly through a spouse and multiple family trusts. The filing states that these trades were made under a pre-arranged Rule 10b5-1 trading plan entered into on May 2, 2025, covering a tranche of 294,000 stock options that expire on March 15, 2026 and running until the earlier of exhaustion of that tranche or December 31, 2025.
United Therapeutics (UTHR) president and COO reported option exercises and related share sales carried out on 11/17/2025 through family trusts. Trusts beneficially owned by the executive exercised stock options for 14,625 shares at an exercise price of $135.42 and for 2,625 and 5,250 shares at $146.03 per share. The resulting common stock was then sold in market transactions at a reported price of $470.4336 per share, leaving those trusts with no directly held common stock from these specific transactions. The Form 4 notes that the activity was conducted under a Rule 10b5‑1 trading plan entered into on August 7, 2024, and that the executive continues to hold derivative securities (stock options) indirectly through the trusts.
United Therapeutics Corporation (UTHR) reported insider activity by its CFO and Treasurer. On November 17, 2025, the officer exercised stock options to acquire 10,688 and 10,312 shares of common stock at an exercise price of $146.03 per share. Most of these shares were then sold the same day in a series of market transactions at weighted average prices ranging from $464.3842 to $476.4706, executed under a pre-arranged Rule 10b5-1 trading plan entered into on August 5, 2025. Following these transactions, the officer directly owns 8,118 shares of United Therapeutics common stock and holds 21,517 stock options.
United Therapeutics Corporation reported insider transactions by its Chairperson and CEO in a Form 4 filing. On November 14, 2025 and November 17, 2025, the reporting person exercised a total of 8,000 stock options at an exercise price of $120.26 per share and sold an aggregate of 8,000 shares of common stock in multiple market transactions at weighted average prices ranging from about $461.54 to $468.39. Following these trades, the reporting person held 130 shares directly and 90,000 stock options beneficially, along with additional indirect holdings through a spouse and several family trusts. The filing notes that these option exercises and sales were made under a pre-arranged Rule 10b5-1 trading plan entered on May 2, 2025, which continues until a tranche of 294,000 stock options expiring on March 15, 2026 is exhausted or until December 31, 2025, whichever occurs first.
United Therapeutics (UTHR) reported an insider transaction by its EVP & General Counsel. On 11/13/2025, the officer exercised 11,000 stock options at an exercise price of $135.42 and sold the resulting shares in multiple trades pursuant to a pre‑arranged Rule 10b5-1 plan entered on December 24, 2024. The sales were executed in several tranches at reported weighted average prices, with disclosed trade ranges from $457.83 to $469.09. Following these transactions, the officer beneficially owns 36,781 shares directly.